EFFECTS OF GROSSHEMIN AND GROSSMISIN ON THE ACUTE HYPERLIPIDEMIA MODEL INDUCED BY ETHANOL

Objective: study sesquiterpene lactones grosshemin and grossmisin lipid-lowering properties on the model of acute hyperlipidemia induced by ethanol in rats.
Materials and methods. Rats during 7 days injected into the stomach grosshemin and grossmisin in a dose 10 mg/kg or reference drug nicotinic acid in a dose 25 mg/kg. Hyperlipidemia caused by single introduction of ethanol into the stomach in a dose 5 g/kg. In blood serum of tail vein measured the triacylglycerols, total cholesterol, high density and low density lipoproteins cholesterol, also the level of free fatty acids. Calculated the ratio of high density lipoproteins cholesterol to the amount of low density lipoproteins cholesterol and the index of atherogenicity.
Results. A single dose of ethanol increased serum level of triacylglycerols in 1.9 times, free fatty acids – in 3.2 times, low density lipoproteins – on 44% in comparison with the intact animals indices. It shows the development of acute hyperlipidemia. Serum total cholesterol, high density lipoproteins cholesterol and the index of atherogenicity were not changed. Course sesquiterpene lactones grosshemin and grossmisin introduction against the background of acute hyperlipidemia was accompanied by a decrease in the serum of triacylglycerols levels respectively by 19.8% and 34.1%. Nicotinic acid lowered the content of triacylglycerols by 42.4%. Grosshemin and nicotinic acid reduced the increased level of free fatty acids in the blood serum by 60.7–67.9%. Grossmisin and nicotinic acid decreased by 14.6–17.2% of total cholesterol in the blood serum. In acute hyperlipidemia grosshemin and grossmisin reduced low density lipoproteins cholesterol by 17.6% and 20%, respectively, nicotinic acid – by 15.7%. Both of sesquiterpene lactone and nicotinic acid did not modify the content of high density lipoproteins cholesterol. When introduction grosshemin, grossmisin and nicotinic acid ratio of high density lipoproteins cholesterol to the amount of low density lipoproteins cholesterol significantly increased by 42.8%, 38,6% and 22.1% respectively.
Conclusion. Sesquiterpene lactones grosshemin and grossmisin posses hypolipidemic effect in acute experimental hyperlipidemia caused by the ethanol introduction. Lactones normalize many indices of lipid metabolism, which can be caused by different biochemical targets of these molecules. Lactones, as nicotinic acid, in the model of acute hyperlipidemia decrease in blood serum triacylglycerols, total cholesterol, and low density lipoproteins cholesterol content. Grosshemin and nicotinic acid also reduce the free fatty acids level.

1. Hansson G.K., Robertson A.-K.L., Söderberg-Naucler C. Inflammation and atherosclerosis. Annu. Rev. Pathol. Mech. Dis., 2006, vol. 1, no. 2, pp. 297–329.

2. Atherosclerosis – Diet-induce atherosclerosis/hypercholesterolemia in rodent models. Ed. M.A. Pellizzon. URL: http://www.researchdiets.com/product-literature

3. VanderLaan P.A., Reardon С.А. The unusual suspects: an overview of the minor leucocyte populations in atherosclerosis. J. Lipid Res., 2005, vol. 46, no. 7, pp. 829–838.

4. Bueverova E.L., Drapkina O.M., Ivashkin V.T. Russian Medical News, 2008, vol. 13, no. 1, pp. 17–23 (in Russian).

5. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA, 2001, vol. 285, no. 12, pp. 2486–2497.

6. Vasilenko Yu.K., Lisevitskaya L.I., Frolova L.M., Parfentieva Ye.P., Skulte I.V., Vasilenko A.Yu., Kozharsky V.V., Voskanyan V.L. Chem.-Farm. Journal, 1982, vol. 45, no. 5, pp. 66–70 (in Russian).

7. Shimoda H., Ninomiya K., Nishida N. et al. Antihyperlipidemic sesquiterpenes and new sesquiterpene glycosides from the leaves of artichoke (Cynara scolymus L.): structure requirement and mode of action. Bioorg. Med. Chem. Lett., 2003, vol. 13, no. 2, pp. 223–228.

8. Eliza J., Daisy P., Ignacimuthu S., Duraipandiyan V. Antidiabetic and antilipidemic effect of eremanthin from Costus speciosus (Koen.) Sm., in STZ-induced diabetic rats. Chem. Biol. Interact., 2009, vol. 182, no. 1, pp. 67–72.

9. Kim S.H., Park K.S. Effects of Panax ginseng extract on lipid metabolism in humans. Pharmacol. Res., 2003, vol. 48, no. 5, pp. 511–513.

10. Hennekens C.H. Current perspectives on lipid lowering with statins to decrease risk of cardiovascular disease. Clin. Cardiol., 2001, vol. 24, no. 7, pp. 2–5.

11. Kagarlitsky A.D., Adekenov S.M., Kupriyanov A.N. Sesquiterpene lactones plants of Central Kazahstan. AlmaAta. Science Publ., 1987. 240 p. (in Russian).

12. Guidelines for pre-clinical trials of drugs. Part 1. Ed. A.I. Mironov. Moscow, Grif and Co. Publ., 2013. 944 p. (in Russian).

13. Sapronov N.S., Khnychenko L.K., Okunevich I.V., Gavrovskaya L.K. Potential antiatherosclerotic drugs: novel N-substituted taurinamide derivatives. Adv. Exp. Med. Biol., 2006, vol. 583, pp. 515–521.

14. Bodor E.T., Offermanns S. Nicotinic acid: an old drug with a promising future. Br. J. Pharmacol., 2008, vol. 153, no. 1, pp. 68–75.

15. Ren N., Kaplan R., Hernandez M. et al. Phenolic acids suppress adipocyte lypolisis via activation of the nicotinic acid receptor GRP109A (HM74a/PUMA-G). J. Lipid Res., 2011, vol. 50, no. 5, pp. 908–914.